

Minutes: Draft

Guideline Development Group Meeting

Date and Time:	Type 1 Diabetes in Adults Update Guideline Development Group meeting Tuesday 14th May 2013 10:00-16:00
Venue:	National Clinical Guidelines Centre
Present:	<p>GDG Members Prof Stephanie Amiel Mr Arthur Durrant Dr Michael Flynn Prof Roger Gadsby Dr Peter Hammond Mr Mike Kendall Ms Vicky Ruzsala Dr Stuart Smellie Ms Perdy Van Den Berg</p> <p>Technical Team Dr Bernard Higgins Dr Gus Brookes Ms Nancy Turnbull Ms Rachel O'Mahony Mr Jonathan Nyong Mr Chris Kiff Ms Rhosyn Harris Ms Nancy Pursey Mr Alex Allen</p>
Apologies	<p>Ms Vibhuti Mistry Dr Henrietta Mulnier</p>

In attendance:

NICE Staff:	<p>Claire Ruiz (nee Turner) NICE Commissioning Manger Bhash Naidoo NICE Senior Technical Adviser</p>	
-------------	---	--

Notes

1. **Welcome, introduction and apologies**

The Chair welcomed the group to the sixth meeting. The chairman introduced Dr Gus Brookes who is joining the NCGC technical team and Nancy Pursey, senior project manager, who is taking over from Nancy Turnbull. The GDG expressed their gratitude to Nancy Turnbull for project managing the guideline thus far. Debra Lake has resigned from her role as GDG member. Apologies were received from Vibhuti Mistry and Henrietta Mulnier.

2. **Minutes of the previous meeting**

The GDG reviewed the minutes which were accepted as a true and accurate record of the meeting.

3. **Declarations of interest**

Mike Kendall declared that he has volunteered to test a smartphone app for self-monitoring. It was agreed that Mike can declare and participate for the question looking at technologies for self-monitoring

Roger Gadsby previously declared an interest related to Novo Nordisk and was not present for the reviews of mixed insulin or once vs. twice daily insulin.

Vicky Ruzsala previously declared interests relating to Lily and Boehringer, and was present but did not participate in making recommendations for insulin.

4. **Evidence review: adjunctive non-insulin therapies**

Clinical and cost effectiveness evidence was presented. The GDG discussed the evidence and made recommendations.

5. **Evidence review: continuous glucose monitoring (CGM) vs. self monitoring (SMBG) of blood glucose**

An updated evidence report was presented. Draft recommendations were discussed and will be revisited when the results of the model are available.

6. **Evidence review: mixed insulin**

The clinical and cost effectiveness evidence for mixed insulin was presented and the evidence was discussed. Further work is needed on the evidence report before recommendations can be made. The report will be updated and presented again at a later GDG meeting.

7. **Evidence review: once vs. twice daily insulin**

Clinical and cost effectiveness evidence was presented and discussed. Recommendations will be drafted following further consideration of the evidence when the results of the network meta analysis are available.

8. **Review protocols**

The GDG reviewed the protocol for the HbA1c targets question and updated it.

Notes

9. Date, time and venue of the next meeting

The chair thanked participants for attending and confirmed the date of the next meeting.

The next GDG meeting takes place on Tuesday 18th June 2013, 1000 – 1600.

Venue: National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ